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Limited data are available on the performance of different automated extraction platforms and commercially
available quantitative real-time PCR (QRT-PCR) methods for the quantitation of cytomegalovirus (CMV)
DNA in plasma. We compared the performance characteristics of the Abbott mSample preparation system
DNA kit on the m24 SP instrument (Abbott), the High Pure viral nucleic acid kit on the COBAS AmpliPrep
system (Roche), and the EZ1 Virus 2.0 kit on the BioRobot EZ1 extraction platform (Qiagen) coupled with the
Abbott CMV PCR kit, the LightCycler CMV Quant kit (Roche), and the Q-CMV complete kit (Nanogen), for
both plasma specimens from allogeneic stem cell transplant (Allo-SCT) recipients (n 42) and the OptiQuant
CMV DNA panel (AcroMetrix). The EZ1 system displayed the highest extraction efficiency over a wide range
of CMV plasma DNA loads, followed by the m24 and the AmpliPrep methods. The Nanogen PCR assay yielded
higher mean CMV plasma DNA values than the Abbott and the Roche PCR assays, regardless of the platform
used for DNA extraction. Overall, the effects of the extraction method and the QRT-PCR used on CMV plasma
DNA load measurements were less pronounced for specimens with high CMV DNA content (>10,000 copies/
ml). The performance characteristics of the extraction methods and QRT-PCR assays evaluated herein for
clinical samples were extensible at cell-based standards from AcroMetrix. In conclusion, different automated
systems are not equally efficient for CMV DNA extraction from plasma specimens, and the plasma CMV DNA
loads measured by commercially available QRT-PCRs can differ significantly. The above findings should be
taken into consideration for the establishment of cutoff values for the initiation or cessation of preemptive
antiviral therapies and for the interpretation of data from clinical studies in the Allo-SCT setting.
Quantitative real-time PCR (QRT-PCR) assays are being
increasingly used for the surveillance of active cytomegalovirus
(CMV) infection in allogeneic stem cell transplant (Allo-SCT)
recipients (23). Several CMV QRT-PCR assays targeting dif-
ferent CMV genes and using different chemistries are com-
mercially available (23). The analytical performance and clin-
ical usefulness of these assays have been assessed, mostly in
comparison with the pp65 antigenemia test or quantitative
endpoint PCR assays (1, 2, 6, 9, 10–13, 15, 17, 19, 21, 22,
24–26). Limited data are available on how these QRT-PCR
tests compare to each other for the quantitation of CMV
plasma DNAemia (5, 11, 12, 18, 24). This information may
allow, at least to some extent, direct comparisons of CMV
DNA loads measured at different centers.
Nucleic acid extraction is a critical step in QRT-PCR testing,
and it has been shown to be a major source of assay variability
in viral DNA quantitation (7). Automated nucleic acid extrac-
tion systems are less time-consuming, less prone to analytical
errors, and, overall, more efficient than manual methods. A
few studies have directly compared the extraction efficiency of
different automated systems for the quantitation of CMV
DNA in plasma by QRT-PCR assays (5, 14, 16). In this study,
we evaluated the performance characteristics of three auto-
mated DNA extraction platforms coupled with three different
QRT-PCR assays for CMV DNA quantitation in plasma ob-
tained from Allo-SCT recipients.
MATERIALS AND METHODS
Clinical specimens and reference standards. A total of 42 plasma specimens
were included in the study. These samples were obtained from 23 patients (11
males and 12 females; mean age, 48 years; range, 19 to 65 years) who had
undergone related/HLA-matched (n  10), related/HLA-mismatched (n  3),
unrelated/HLA-matched (n  7), or unrelated/HLA-mismatched (n  3) pe-
ripheral blood Allo-SCT at our institution between March 2009 and October
2010. Paired CMV serostatuses of donors (D) and recipients (R) were D/R in
16 cases and D/R in the remaining 7 cases. The underlying disease was of
hematological origin in all patients. All plasma specimens were obtained within
the first 120 days following Allo-SCT. The aliquots of plasma used in the current
study were frozen at 20°C shortly after collection and had not been thawed
prior to use for the analyses described herein. The specimens were grouped into
three categories according to the CMV DNA loads measured using the Abbott
real-time PCR assay (coupled with the Abbott mSample preparation system
DNA kit on the m24 SP instrument), the method currently used at our institution
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(see below): (i) 10 samples with low CMV DNA contents (1,000 copies/ml;
mean, 394 copies/ml; range, 25 to 734 copies/ml); (ii) 22 samples with interme-
diate CMV DNA loads (1,000 and 10,000 copies/ml; mean, 5,126 copies/ml;
range, 1,088 to 9,824 copies/ml), and (iii) 10 samples with high CMV DNA loads
(10,000 copies/ml; mean, 23,766; range, 10,961 to 48,406 copies/ml). Plasma
specimens were tested once by each nucleic acid extraction method/QRT-PCR
assay combination. A unique aliquot of each plasma specimen was used for all
the analyses reported herein.
The OptiQuant CMV DNA quantification panel (AcroMetrix Corp., Benicia,
CA), which contains normal human plasma spiked with four concentrations of
CMV strain Ad169, was used to compare the performance characteristics of the
extraction methods and the QRT-PCR assays evaluated herein. The standards
were tested in two different runs at 100, 1,000, 5,000, and 10,000 copies/ml.
Dilutions were prepared from the panel using the NAT dilution matrix
(AcroMetrix).
Nucleic acid extraction. The following automated nucleic acid extraction
methods were evaluated: the Abbott mSample preparation system DNA kit on
the m24 SP instrument (Abbott Diagnostics, IL), the High Pure viral nucleic acid
kit on the COBAS AmpliPrep system (Roche Diagnostics, Mannheim, Ger-
many), and the EZ1 Virus 2.0 kit (Qiagen, Valencia, CA) on the BioRobot EZ1
extraction platform (Qiagen, Valencia, CA), following the instructions of the
respective manufacturers. The DNA extractions were performed using 500 l of
plasma for the m24 SP and COBAS AmpliPrep systems with an elution volume
of 70 l in both methods and using 400 l for the BioRobot EZ-1 (maximum
volume) with an elution volume of 60 l.
QRT-PCR assays. The following QRT-PCR assays were evaluated. The Ab-
bott CMV PCR kit (produced by Qiagen GmbH, Hilden, Germany, for Abbott
Diagnostics, Des Plaines, IL), which amplifies a 105-bp region of the UL122
(IE-1) gene, was evaluated using the m2000RT system (Abbott Molecular, IL).
The limit of detection of the assay is approximately 25 copies/ml (9). The
LightCycler CMV Quant kit (Roche Diagnostics GmbH, Mannheim, Germany),
which targets the UL54 DNA polymerase gene of CMV, was evaluated using the
LightCycler 2.0 instrument (Roche). The limit of detection of this assay is
approximately 250 to 300 copies/ml for plasma specimens (5). The Q-CMV
complete kit (Cepheid, Turin, Italy; manufactured by Nanogen Advanced Diag-
nostics), which targets the exon 4 region of the CMV major immediate early gene
(UL123), was evaluated using the LightCycler 2.0 instrument (Roche). Accord-
ing to the manufacturer, the limit of detection of this assay is approximately 700
copies/ml. The mean intra-assay variability (percent coefficient of variation) of
the above-described QRT-PCR assays for noncellular specimens is 0.2 log10
over the linear range of the assays (according to the manufacturers). All assays
were performed following the instructions of the respective manufacturers. The
three QRT-PCR assays were approved via the CE-labeling system.
Statistical methods. The data were log10 transformed prior to analysis. Dif-
ferences between mean CMV DNA loads measured using the three assays
(coupled with the three automated extraction methods) were analyzed using
Pearson’s chi-square test. Any quantitative correlations between the CMV DNA
loads obtained using the different extraction methods and the QRT-PCR assays
were detected using Pearson’s correlation tests. The method of Bland and Alt-
man (3) was used to assess the agreement between viral loads measured using the
different analytical systems. Statistical calculations were performed with the aid
of the SPSS 17.0 program (SPSS Inc., Chicago, IL); P values of 0.05 were
considered statistically significant.
RESULTS
Comparison of extraction efficiencies of the automated
methods. The CMV DNA loads in the nucleic acid extracts
from the plasma specimens obtained using the three auto-
mated extraction methods were significantly correlated, irre-
spective of the QRT-PCR assay employed for quantitation
(P  0.001 for all correlations). The data obtained using the
Abbott QRT-PCR kit test are shown in Fig. 1. The extraction
efficiency of the EZ1 platform was superior to that of the other
two systems (Table 1). The CMV DNA loads measured using
the three QRT-PCR assays following extraction with the EZ1
BioRobot were consistently higher than those obtained after
extraction by the m24 SP system. The differences in the CMV
DNA loads measured following extraction by these platforms
varied depending on the QRT-PCR assay used and the CMV
DNA content of the specimen. For specimens with 1,000
copies/ml, the differences in the mean CMV DNA loads
ranged from 0.10 log10 copies/ml (P  0.280) in the Nanogen
PCR assay to 0.25 log10 copies/ml (P  0.07) in the Abbott
PCR assay. For specimens with a higher CMV DNA content
(10,000 CMV DNA copies/ml), the differences were less
marked and ranged from 0.15 log10 copies/ml (P  0.157) in
the Abbott PCR assay to 0.01 log10 copies/ml (P  0.853) in
the Nanogen PCR assay. However, the differences were more
striking when the extraction efficiency of the EZ1 BioRobot
was compared to that of the AmpliPrep system. In effect, for
specimens with 1,000 copies/ml, the mean differences ranged
from 0.66 log10 copies/ml (P  0.001) in the Abbott PCR
assay to 0.27 log10 copies/ml (P  0.005) in the Nanogen PCR
assay. For specimens with intermediate CMV DNA loads, the
differences ranged from 0.41 log10 copies/ml (P  0.001) in
the Roche PCR assay to 0.33 log10 copies/ml (P  0.001) in
the Nanogen PCR. The differences were also significant for
specimens with 10,000 copies/ml (P  0.019 in the Abbott
PCR assay; P  0.014 in the Roche PCR assay; P  0.005 in
the Nanogen PCR assay). Finally, the m24 SP system displayed
greater extraction efficiency than the AmpliPrep method over
the entire range of CMV DNA concentrations, irrespective of
the QRT-PCR employed. Nevertheless, the differences reached
statistical significance only when the specimens were analyzed by
the Nanogen PCR (P  0.026 for specimens with 1,000 copies/
ml, P  0.007 for specimens with 1,000 to 10,000 copies/ml, and
P  0.006 for samples with 10,000 copies/ml). As shown in
Table 2, the above differences in the efficiency of CMV DNA
extraction were also observed when the OptiQuant proficiency
panel was tested (at different CMV DNA concentrations, ranging
from 2.0 to 4.0 log10 CMV DNA copies/ml).
Comparison of the performance of QRT-PCR assays. The
Roche PCR assay gave positive results for 31/42 samples fol-
lowing extraction either with the AmpliPrep or with the m24
system and for 32 specimens after extraction with the EZ1
BioRobot. The Nanogen PCR assay yielded positive results for
39, 41, and 42 specimens following extraction with the Ampli-
Prep, the EZ1 BioRobot, and the m24 platforms, respectively.
Finally, the Abbott PCR assay gave positive results for all
specimens extracted with the EZ1 BioRobot and for 41/42 of
specimens extracted with the AmpliPrep platform.
The Nanogen PCR assay yielded significantly higher CMV
DNA loads than the Abbott and the Roche PCR assays, re-
gardless of the platform used for nucleic acid extraction or the
CMV DNA content of the specimen (P  0.042 for all
comparisons between means) (Table 1). In turn, the CMV
DNA loads measured by the Abbott PCR and the Roche PCR
did not differ significantly (P  0.102 for all comparisons
between mean values), regardless of the extraction method
used and the concentration of the CMV DNA specimen (Table
1). When DNA extraction was performed using the most effi-
cient extraction system (the EZ1 BioRobot) we found that (i)
the Nanogen and the Abbott QRT-PCR assays gave CMV
DNA loads differing by less than 0.5 log10 DNA copies/ml in
33/42 samples (78.5%) (Fig. 2A), the Nanogen and the Roche
QRT-PCR assays in 27/32 specimens (84.3%) (Fig. 2B), and
the Roche and the Abbott PCR assays in 31/32 specimens
(96.8%) and (ii) the highest differences in CMV DNA loads
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measured by the PCR assays were found for specimens with
low CMV DNA content (1,000 copies/ml). In keeping with
the above data, the Nanogen PCR assay yielded higher CMV
DNA loads than the Abbott and Roche PCR assays when the
OptiQuant panel was tested, whereas the Roche and Abbott
PCR assays gave equivalent results, irrespective of the extrac-
tion platform used (Table 2). When samples were extracted
using the EZ1 BioRobot, all QRT-PCR assays gave CMV
DNA loads above the expected values.
Comparison of CMV DNA loads measured using the Abbott
and Roche reagents and extraction platforms. The CMV DNA
loads obtained using the Abbott and Roche reagents (QRT-
PCRs coupled with the respective extraction methods) were
directly compared for specimens that tested positive in both
systems (n  32). CMV DNA loads differing by less than 0.5
log10 DNA copies/ml were obtained by both methods in all but
one sample (Fig. 3). In fact, the mean CMV DNA load values
obtained using both systems were not significantly different for
either the specimens with intermediate CMV DNA loads (P 
0.547) or samples with high CMV DNA content (P  0.106)
(Table 1). For specimens with 1,000 to 10,000 copies/ml, the
CMV loads measured using the Roche assay were slightly
higher than those obtained using the Abbott PCR assay (mean,
1.1-fold; range, 0.3- to 2.1-fold). Conversely, for specimens
with 10,000 copies/ml, the Abbott PCR assay gave higher
CMV DNA values than the Roche PCR assay (mean, 1.49-
fold; range, 0.77- to 2.96-fold).
DISCUSSION
Limited data are available on how commercially available
QRT-PCR assays compare to each other for the measurement
FIG. 1. Correlation and linear regression analysis of cytomegalovirus (CMV) DNA load values (copies/ml) obtained for all positive specimens
by the Abbott CMV PCR kit following DNA extraction using the Abbott mSample preparation system DNA kit on the m24 SP instrument (M24),
the High Pure viral nucleic acid kit on the COBAS AmpliPrep system (AMPLIPREP), and the EZ1 Virus 2.0 kit on the BioRobot EZ1 extraction
platform (EZ).
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of CMV DNA loads in plasma (5, 11, 12, 18, 24). Likewise,
there are scarce data published on the performance of auto-
mated extraction systems for CMV plasma DNA quantitation
(5, 11, 14–16, 20). The above information could, to some ex-
tent, allow the direct comparison and interpretation of CMV
DNA loads obtained using different methods. In the current
study, a comparative evaluation of three widely used auto-
mated systems for DNA extraction coupled with three com-
mercially available QRT-PCR assays for the quantitation of
cytomegalovirus DNA in plasma was performed for both clin-
ical specimens from Allo-SCT recipients and the OptiQuant
proficiency panel. Specimens were grouped into three catego-
ries according to the CMV DNA loads measured using Abbott
reagents and the m24 SP platform (Abbott). We found consis-
tent differences in the nucleic acid extraction efficiencies of the
different automated systems. Although CMV DNA loads in
the nucleic acid extracts from the plasma specimens obtained
by using different methods correlated significantly, irrespective
of the QRT-PCR assay employed for quantitation, the extrac-
tion efficiency of the EZ1 platform was superior to those of the
Abbott m24 SP and AmpliPrep systems, both for clinical spec-
TABLE 1. Cytomegalovirus (CMV) DNA load values in plasma
obtained with three different QRT-PCR assays coupled to
three distinct automated extraction systems
QRT-PCR assay and
extraction system
CMV DNA load, log10 copies/ml, for groupa:
3 (n  10) 3–4 (n  22) 4 (n  10)
Abbottb
m24 2.55 (0.19) 3.61 (0.31) 4.33 (0.18)
AmpliPrep 2.14 (0.77) 3.43 (0.38) 4.20 (0.23)
EZ1 2.80 (0.17) 3.80 (0.41) 4.48 (0.26)
Rochec
m24 ND 3.79 (0.37) 4.38 (0.23)
AmpliPrep ND 3.63 (0.31) 4.17 (0.23)
EZ1 ND 4.04 (0.31) 4.47 (0.25)
Nanogend
m24 3.22 (0.15) 4.03 (0.26) 4.81 (0.20)
AmpliPrep 3.05 (0.11) 3.80 (0.26) 4.47 (0.28)
EZ1 3.32 (0.18) 4.13 (0.30) 4.82 (0.21)
a Specimens were subgrouped into three categories according to CMV DNA
loads measured by using the Abbott real-time PCR assay (coupled with the
Abbott mSample preparation system DNA kit on the m24 SP instrument). Data
are reported as mean values (standard deviation) of CMV DNA loads quanti-
tated in specimens testing positive by a given QRT-PCR assay. ND, not detected.
b One of 10 specimens extracted with the AmpliPrep method tested negative
by the Abbott QRT-PCR.
c Only one out of 10 specimens with3 log10 copies/ml extracted with the m24
SP and AmpliPrep systems and two extracted with the EZ1 system tested positive
by the Roche QRT-PCR. Two specimens with CMV DNA loads between 3 and
4 log10 copies/ml extracted with the m24 SP, AmpliPrep, and EZ1 methods
tested negative by the Roche QRT-PCR.
d Three specimens (3 log10 copies/ml) extracted with the AmpliPrep system
and one (3 log10 copies/ml) extracted with the EZ1 system tested negative by
the Nanogen QRT-PCR.
TABLE 2. Cytomegalovirus (CMV) DNA values obtained with
three QRT-PCR assays coupled with three automated extraction
methods with the OptiQuant proficiency panel
QRT-PCR assay and
extraction system
CMV DNA load in OptiQuant standards
(log10 copies/ml) per dilutiona
2.0 3.0 3.7 4.0
Abbott
m24 1.58 2.61 3.46 3.93
AmpliPrep 1.57 2.28 3.23 3.83
EZ1 1.63 3.11 3.78 4.01
Roche
m24 ND 2.56 3.48 3.92
AmpliPrep ND 2.41 3.32 3.80
EZ1 ND 3.11 3.87 4.04
Nanogen
m24 ND ND 3.60 3.94
AmpliPrep ND ND 3.41 3.92
EZ1 ND 3.28 3.94 4.05
a Dilutions of the OptiQuant standards were prepared from the panel using
the NAT dilution matrix (AcroMetrix). Data are reported as mean results of two
experiments.
FIG. 2. Bland-Altman representation of CMV DNA loads (copies/
ml) measured using the Abbott CMV PCR kit in the m2000RT
(ABBOTT), the LightCycler CMV Quant kit in the Light Cycler 2.0
instrument (ROCHE), and the Q-CMV complete kit in the LightCy-
cler 2.0 instrument (NANOGEN), following DNA extraction by the
EZ1 Virus 2.0 kit on the BioRobot EZ1 extraction platform.
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imens (despite using a lower starting volume of plasma) and
for the OptiQuant standards. In turn, the m24 SP system dis-
played greater extraction efficiency than the AmpliPrep system
over the entire range of CMV DNA loads and irrespective of
the QRT-PCR assay employed. Nevertheless, the differences
between the latter two methods appeared to be subtle and
reached statistical significance only when the specimens were
analyzed using the Nanogen PCR assay. The impact of auto-
mated extraction methods on CMV DNA quantitation has also
been noted in other studies. Caliendo et al. (5) found substan-
tial differences in mean viral loads measured in plasma samples
by the artus CMV LC/TM/RG PCR Kit (Qiagen, Valencia,
CA)—an assay equivalent to the Abbott PCR kit used in the
present study—depending upon the automated extraction
method used (MagNA pure from Roche versus NucliSens
easyMAG from bioMe´rieux). Miller et al. (16) reported that
the QIAsymphony platform (Qiagen) displayed greater extrac-
tion efficiency than the BioRobot EZ1 for CMV DNA quan-
titation with the QRT-PCR ASR (analyte-specific reagents)
from Roche (equivalent to the LightCycler CMV Quant kit
used in the present study).
Whole blood is routinely used at many centers as the sample
material for monitoring of active CMV infection in Allo-SCT
recipients. Whole blood specimens yield higher CMV DNA
loads than plasma samples and permit the earlier detection of
active CMV infection in this clinical setting (23). In a prior
study (14), differences in the performance of several auto-
mated extraction methods for CMV DNA quantitation in
whole blood specimens using “in-house” QRT-PCR assays
were reported. Overall, the magnitude of these differences was
slightly higher than those observed in the current study for
plasma specimens. This is a clinically relevant issue that must
be thoroughly addressed in future studies. In the current study,
the differences between the EZ1 and the other two automated
extraction systems were particularly marked when specimens
with low CMV DNA loads (specimens with 1,000 copies/ml)
were analyzed, and their magnitude depended on the QRT-
PCR used.
The analytical performance of commercially available QRT-
PCR assays has mostly been compared with that of the pp65
antigenemia test or quantitative endpoint PCR assays (1, 2, 6,
9, 10–13, 15, 17, 19, 21, 22, 24–26). Nevertheless, a few studies
directly compared the performance of these assays for the
quantitation of CMV plasma DNAemia (5, 11, 12, 18, 24). In
addition, to the best of our knowledge, data on the perfor-
mance of the QRT-PCR from Nanogen have not been pub-
lished. Our data indicated the following observations. (i) The
QRT-PCR assay from Abbott was more sensitive than those
from Roche and Nanogen. This was expected on the basis of
previously published data (5, 9) and the specifications of the
manufacturers. Nevertheless, our data suggested that the sen-
sitivity of the Nanogen PCR assay may have been underesti-
mated. (ii) The QRT-PCR assay from Nanogen yielded signif-
icantly higher CMV DNA loads than the other two PCR
assays, regardless of the platform used for DNA extraction and
the CMV DNA contents of the specimens. These differences
were overall of greater magnitude than those that would be
expected according to the intra-assay variability of the respec-
tive QRT-PCR assays, and they were greatest at the lowest
CMV DNA concentration. Nevertheless, the CMV DNA loads
measured with the Nanogen PCR assay and those quantitated
by the Abbott and Roche PCR methods, following extraction
with the most efficient system (EZ1 BioRobot), differed by less
than 0.5 log10 copies/ml for 78.5% and 84.3% of samples,
which, as suggested by Pang et al. (17, 18), represents the
upper limit for divergence from the expected reference values
for adequate interlaboratory comparisons of CMV DNA loads
with clinical purposes. The CMV DNA loads measured by the
Abbott PCR and the Roche PCR assays were not significantly
different, irrespective of the extraction method and the CMV
DNA content of specimens. In fact, the differences found were
less than 0.5 log10 copies/ml for 96.6% of plasma samples.
Interestingly, we found that the CMV DNA loads obtained
using the Abbott QRT-PCR assay coupled with the m24 SP
extraction system were slightly higher than those obtained by
the Roche QRT-PCR assay coupled with the AmpliPrep ex-
traction method for specimens with high CMV DNA concen-
trations (10,000 copies/ml), but they were slightly lower for
specimens with intermediate CMV DNA contents (1,000 but
10,000 copies/ml). In this context, Hanson et al. (12) com-
pared the Roche CMV UL54 analyte-specific reagent (equiv-
alent to the Roche QRT-PCR assay used in the present study)
and the Qiagen realArt CMV LightCycler PCR reagent (es-
sentially the same product as the Abbott QRT-PCR assay used
in the current study) and found that the CMV plasma DNA
loads measured using the Qiagen assay tended to be lower than
those measured with the Roche reagent when using clinical
samples but not when employing the OptiQuant panel, in both
cases after DNA extraction with the Roche MagnaPure auto-
mated platform. (iii) The performance characteristics of the
QRT-PCR assays evaluated herein for clinical samples were
extensible at cell-based standards from AcroMetrix, despite
relevant differences in viral DNA conformation (highly frag-
mented CMV DNA in plasma specimens and large amounts of
concatemers in cell-derived preparations) (4, 5).
The above findings have relevant implications for the ther-
apeutic management of active CMV infection in Allo-SCT
recipients. Threshold values of CMV plasma DNAemia for
initiation of preemptive antiviral therapy in the Allo-SCT set-
ting vary between centers, but they are usually set at around
FIG. 3. Bland-Altman representation of CMV DNA loads (copies/
ml) measured using the Abbott CMV PCR kit in the m2000RT
(ABBOTT) after extraction by the Abbott mSample preparation sys-
tem DNA kit on the m24 SP instrument and those measured by the
LightCycler CMV Quant kit in the Light Cycler 2.0 instrument
(ROCHE), following extraction by the High Pure viral nucleic acid kit
on the COBAS AmpliPrep system.
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500 to 1,000 copies/ml (23). In this context, our data under-
score the fact that the choice of the automated extraction
method and the QRT-PCR assay for the surveillance of active
CMV infection may critically determine the decision to initiate
or defer preemptive antiviral therapy and thus may ultimately
influence the patient’s clinical outcome. Thus, the CMV
plasma DNA cutoff level triggering the implementation of an-
tiviral therapy must be set taking into consideration the intrin-
sic performance of both the nucleic acid extraction method and
the QRT-PCR assay employed. The recent advent of the 1st
World Health Organization International Standard for CMV
for Nucleic Acid Amplification (NAT)-Based Assays (8)
should allow researchers to work out the equivalencies be-
tween CMV DNA loads measured by different QRT-PCR
methods coupled with distinct nucleic acid extraction methods,
ultimately permitting the establishment of clinically safe CMV
DNA thresholds triggering therapeutic intervention.
In summary, our data indicated that there are substantial
differences in nucleic acid extraction efficiency between auto-
mated systems and in CMV DNA loads measured using dif-
ferent commercially available QRT-PCR assays, which may
impact on therapeutic decisions and should be taken into con-
sideration for the interpretation of data from clinical studies.
In addition, our results support the feasibility of comparing
published clinical and virological data from patients who were
monitored using the Abbott CMV PCR kit and the Roche
LightCycler CMV Quant kit or their equivalent commercial
products.
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